WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317126
Description: Guanabenz acetate is an α2A-AR adrenergic agonist and IGRS (imidazoline I2 binding site) selective ligand. Guanabenz acetate is an activator of alpha2B-AR (α2b-adrenergic receptor) and alpha2C-AR (α2c-adrenergic receptor). It is also used as an antihypertensive drug to treat high blood pressure.
MedKoo Cat#: 317126
Name: Guanabenz Acetate
Chemical Formula: C10H12Cl2N4O2
Molecular Weight: 291.13
Elemental Analysis: C, 41.26; H, 4.15; Cl, 24.35; N, 19.24; O, 10.99
Synonym: Wytensin, WY-8678, WY 8678, WY8678, EIPA
IUPAC/Chemical Name: [(2,6-Dichlorobenzylidene)amino]guanidine acetate
InChi Key: MCSPBPXATWBACD-GAYQJXMFSA-N
InChi Code: InChI=1S/C8H8Cl2N4.C2H4O2/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12;1-2(3)4/h1-4H,(H4,11,12,14);1H3,(H,3,4)/b13-4+;
SMILES Code: NC(N/N=C/C1=C(Cl)C=CC=C1Cl)=N.CC(O)=O
Appearance: White to off-white solid powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 291.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Igaki N, Yamada H, Oimomi M, Kasuga M. The effective inhibition of the Maillard reaction by guanabenz acetate, and its relevance to the prevention of diabetic complications. Clin Chim Acta. 1991 May 31;199(1):113-5. PubMed PMID: 1934497.
2: Kotake H, Kinugawa T, Hirai S, Matsumoto T, Fukuki M, Hasegawa J, Mashiba H. Effects of guanabenz acetate on the pacemaker activity of rabbit sinoatrial node cells. Arch Int Pharmacodyn Ther. 1989 Jul-Aug;300:209-17. PubMed PMID: 2619423.
3: Spritzer N, Spritzer TS, Rodrigues R. [Guanabenz acetate and serum lipids. Sequential evaluation during one year]. Arq Bras Cardiol. 1988 Aug;51(2):193-7. Portuguese. PubMed PMID: 3075114.
4: LaRusso P, Jessup SA, Rogers FJ, Rogers JC. Sinoatrial and atrioventricular dysfunction associated with the use of guanabenz acetate. Can J Cardiol. 1988 Apr;4(3):146-8. PubMed PMID: 3378199.
5: Harvengt C. Drugs recently released in Belgium. Guanabenz acetate, isotretinoin and etretinate. Acta Clin Belg. 1986;41(1):60-3. PubMed PMID: 3458348.
6: Tennant FS Jr, Rawson RA. Guanabenz acetate: a new, long-acting alpha-two adrenergic agonist for opioid withdrawal. NIDA Res Monogr. 1984 Mar;49:338-43. PubMed PMID: 6090917.
7: Capuzzi DM, Cevallos WH. Inhibition of hepatic cholesterol and triglyceride synthesis by guanabenz acetate. J Cardiovasc Pharmacol. 1984;6 Suppl 5:S847-52. PubMed PMID: 6084138.
8: Grenfell RF. Double-blind study of guanabenz acetate in hypertensive patients. South Med J. 1983 Feb;76(2):199-201. PubMed PMID: 6337405.